Rezolute (RZLT)

NASDAQ:RZLT

RZLT

Rezolute

RESEARCH TOOLSreports

Rezolute (RZLT) Stock Forecast & Price Target

748 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RZLT Analyst Ratings

Moderate Buy

3 Buy

2 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Rezolute

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RZLT Stock 12 Month Forecast

Average Price Target

$5.00

▲(75.44% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Rezolute in the last 3 months. The average price target is $5.00 with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 75.44% change from the last price of $2.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","3.25":"$3.25","5.5":"$5.5","7.75":"$7.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.25,5.5,7.75,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,3.2830769230769232,3.4261538461538463,3.5692307692307694,3.7123076923076925,3.8553846153846156,3.9984615384615383,4.141538461538461,4.2846153846153845,4.427692307692308,4.570769230769231,4.713846153846154,4.856923076923077,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,3.2830769230769232,3.4261538461538463,3.5692307692307694,3.7123076923076925,3.8553846153846156,3.9984615384615383,4.141538461538461,4.2846153846153845,4.427692307692308,4.570769230769231,4.713846153846154,4.856923076923077,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.14,3.2830769230769232,3.4261538461538463,3.5692307692307694,3.7123076923076925,3.8553846153846156,3.9984615384615383,4.141538461538461,4.2846153846153845,4.427692307692308,4.570769230769231,4.713846153846154,4.856923076923077,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.43,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.225,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.87,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$5.00

Average Price Target$5.00

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas Tsao

H.C. Wainwright

Buy

75.44%

Upside

Reiterated

03/30/26

Analysts Offer Insights on Healthcare Companies: Sight Sciences (NASDAQ: SGHT), Atara Biotherapeutics (NASDAQ: ATRA) and Rezolute (NASDAQ: RZLT)

Pete Stavropoulos

Cantor Fitzgerald

―

Hold

―

Reiterated

03/25/26

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Rezolute (NASDAQ: RZLT) and Demant (Other OTC: WILLF)

Yun Zhong

Wedbush

$2→$5

Buy

75.44%

Upside

Upgraded

03/25/26

Rezolute upgraded to Outperform from Neutral at WedbushRezolute upgraded to Outperform from Neutral at Wedbush

Julian Harrison

BTIG

Buy

75.44%

Upside

Reiterated

03/24/26

Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT)

Matt Hewitt

Craig-Hallum

―

Hold

―

Assigned

03/24/26

Analysts Conflicted on These Healthcare Names: Rezolute (NASDAQ: RZLT), Celcuity (NASDAQ: CELC) and Neurogene (NASDAQ: NGNE)

Jason McCarthy

Maxim Group

$20→$4

Buy

40.35%

Upside

Reiterated

12/12/25

Rezolute price target lowered to $4 from $20 at MaximRezolute price target lowered to $4 from $20 at Maxim

Debjit Chattopadhyay

Guggenheim

$15→$6

Buy

110.53%

Upside

Reiterated

12/11/25

Rezolute price target lowered to $6 from $15 at GuggenheimRezolute price target lowered to $6 from $15 at Guggenheim

Jason Butler

Citizens JMP

―

Hold

―

Downgraded

12/11/25

Rezolute downgraded to Market Perform from Outperform at CitizensRezolute downgraded to Market Perform from Outperform at Citizens

Maury Raycroft

Jefferies

$15→$20

Buy

601.75%

Upside

Reiterated

12/08/25

Rezolute price target raised to $20 from $15 at JefferiesRezolute price target raised to $20 from $15 at Jefferies

Catherine Novack

JonesTrading

$12

Buy

321.05%

Upside

Reiterated

05/15/25

Rezolute's Ersodetug Shows Promise in Phase 3 Trials for CHI, Reinforcing Buy Rating and $12 Price Target

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas Tsao

H.C. Wainwright

Buy

75.44%

Upside

Reiterated

03/30/26

Analysts Offer Insights on Healthcare Companies: Sight Sciences (NASDAQ: SGHT), Atara Biotherapeutics (NASDAQ: ATRA) and Rezolute (NASDAQ: RZLT)

Pete Stavropoulos

Cantor Fitzgerald

―

Hold

―

Reiterated

03/25/26

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Rezolute (NASDAQ: RZLT) and Demant (Other OTC: WILLF)

Yun Zhong

Wedbush

$2→$5

Buy

75.44%

Upside

Upgraded

03/25/26

Rezolute upgraded to Outperform from Neutral at WedbushRezolute upgraded to Outperform from Neutral at Wedbush

Julian Harrison

BTIG

Buy

75.44%

Upside

Reiterated

03/24/26

Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT)

Matt Hewitt

Craig-Hallum

―

Hold

―

Assigned

03/24/26

Analysts Conflicted on These Healthcare Names: Rezolute (NASDAQ: RZLT), Celcuity (NASDAQ: CELC) and Neurogene (NASDAQ: NGNE)

Jason McCarthy

Maxim Group

$20→$4

Buy

40.35%

Upside

Reiterated

12/12/25

Rezolute price target lowered to $4 from $20 at MaximRezolute price target lowered to $4 from $20 at Maxim

Debjit Chattopadhyay

Guggenheim

$15→$6

Buy

110.53%

Upside

Reiterated

12/11/25

Rezolute price target lowered to $6 from $15 at GuggenheimRezolute price target lowered to $6 from $15 at Guggenheim

Jason Butler

Citizens JMP

―

Hold

―

Downgraded

12/11/25

Rezolute downgraded to Market Perform from Outperform at CitizensRezolute downgraded to Market Perform from Outperform at Citizens

Maury Raycroft

Jefferies

$15→$20

Buy

601.75%

Upside

Reiterated

12/08/25

Rezolute price target raised to $20 from $15 at JefferiesRezolute price target raised to $20 from $15 at Jefferies

Catherine Novack

JonesTrading

$12

Buy

321.05%

Upside

Reiterated

05/15/25

Rezolute's Ersodetug Shows Promise in Phase 3 Trials for CHI, Reinforcing Buy Rating and $12 Price Target

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rezolute

3 Months

xxx

Success Rate

11/19 ratings generated profit

Average Return

+28.69%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +28.69% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

13/19 ratings generated profit

Average Return

+76.25%

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +76.25% per trade.

2 Years

xxx

Success Rate

10/19 ratings generated profit

Average Return

+74.02%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 52.63% of your transactions generating a profit, with an average return of +74.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RZLT Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RZLT has received 9 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. RZLT average Analyst price target in the past 3 months is 5.00.

Each month's total comprises the sum of three months' worth of ratings.

RZLT Financial Forecast

RZLT Earnings Forecast

The previous quarter’s earnings for RZLT were -$0.22.

No data currently available

RZLT Sales Forecast

The previous quarter’s earnings for RZLT were $0.00.

RZLT Stock Forecast FAQ

What is RZLT’s average 12-month price target, according to analysts?

Based on analyst ratings, Rezolute’s 12-month average price target is 5.00.

What is RZLT’s upside potential, based on the analysts’ average price target?

Rezolute has 75.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RZLT a Buy, Sell or Hold?

Rezolute has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.

What is Rezolute’s price target?

The average price target for Rezolute is 5.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.00 ,the lowest forecast is $5.00. The average price target represents 75.44% Increase from the current price of $2.85.

What do analysts say about Rezolute?

Rezolute’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of RZLT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Rezolute (RZLT) Stock Forecast & Price Target

RZLT Analyst Ratings

RZLT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Rezolute

RZLT Analyst Recommendation Trends

RZLT Financial Forecast

RZLT Earnings Forecast

RZLT Sales Forecast

RZLT Stock Forecast FAQ

Detailed List of Analyst Forecasts